Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von GraveDigger 

Bluebird Bio Inc. diskutieren

Bluebird Bio Inc.

WKN: A1W025 / Symbol: BLUE / Name: bluebird bio / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

0,37 €
-0,40 %

bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) 19,45 %
Kursziel 1,90
Veränderung
Endet am 15.11.25

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 38,48
Veränderung
Endet am 31.12.25

bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Barclays PLC from $2.00 to $40.00. They now have an "overweight" rating on the stock.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 7,38
Veränderung
Endet am 31.03.26

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $40.00 to $8.00. They now have an "overweight" rating on the stock.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for BLUE provided by MarketBeat